A6NJR5
Putative speedy protein-like protein 3
Also known as: SPDL3_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for A6NJR5 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
290 residues, UniProt reviewed canonical sequence.
>A6NJR5|A6NJR5
1 MQKHYTVAWF LYSAPGVDPS PPCRSLGWKR KKEWSDESEE EPEKELAPEP EETWVVEMLC
61 GLKMKLKQQR VSPILPEHHK DFNSQLAPGV DPSPPHRSFC WKRKREWWDE SEESLEEEPR
121 KVLAPEPEEI WVAEMLCGLK MKLKRRRVSL VLPEHHEAFN RLLEDPVIKR FLAWDKDLRV
181 SDKYLLAMVI AYFSRAGLPS WQYQRIHFFL ALYLANDMEE DDEDPKQNIF YFLYGKTRSR
241 IPLIALFQKL RFQFFCSMSG RAWVSREELE EIQAYDPEHW VWARDRARLSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against A6NJR5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
OntologyGO
Molecular functions
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads A6NJR5 as an antibody target. Whether an autoantibody or antibody against A6NJR5 could matter depends on whether native A6NJR5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
A6NJR5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label A6NJR5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...